IsoRay's Cesium-131 Medical Isotope Used in Milestone Procedure Treating Eye Cancers...

Thu Dec 13, 2007 9:04am EST

* Reuters is not responsible for the content in this press release.

IsoRay's Cesium-131 Medical Isotope Used in Milestone Procedure Treating Eye Cancers at Tufts-New England Medical Center

  First Application Of IsoRay's Breakthrough Isotope beyond Prostate
                                Cancer
BOSTON--(Business Wire)--IsoRay (AMEX:ISR), a leading-edge developer and provider of
brachytherapy seeds for the treatment of prostate cancer and other
solid tumors, announced today that the world's first brachytherapy
implants for cancer treatment of the eye using its Cesium-131 seeds
were performed at Tufts-New England Medical Center on Wednesday,
December 12, 2007. This marks the first time Cesium-131 has been used
in an application other than the treatment of prostate cancer.

   IsoRay Chairman and CEO Roger Girard said, "Since Cesium-131
received FDA clearance, we've looked forward to when Cesium-131 could
be applied to the fight against other cancers. Treating intraocular
melanoma is a significant milestone for IsoRay as we strive to develop
a variety of delivery tools in treating cancer using Cesium-131."

   Cesium-131 is a proprietary product of IsoRay, and is marketed
under the brand Proxcelan(TM). It has been used in over 1,900 prostate
cancer brachytherapy procedures since October 2004. This fast-acting
medical isotope source has demonstrated strong clinical results in the
treatment of prostate cancer, and is being heralded as the first leap
forward in seed brachytherapy in more than 20 years.

   Three patients received implants for intraocular melanoma, which
were performed with the support of Mark J. Rivard, Ph.D., Associate
Professor of Radiation Oncology at Tufts University School of Medicine
and Chief Medical Physicist at Tufts-New England Medical Center.

   "Cesium-131's unique characteristics, including minimizing healthy
tissue dose, which is a benefit for the patient, may offer significant
clinical advantages," said Rivard, who is also a consultant to IsoRay.

   During the procedures, Cesium-131 brachytherapy seeds--encased in
a small disc-shaped shield (plaque) with a protective gold
backing--were attached to the surface of the patients' eyes over the
area to be treated. The plaques are scheduled to be removed on
December 17, 2007.

   Plaque brachytherapy is a proven radiation treatment for
intraocular melanoma, with Iodine-125 being the most common isotope
associated with this radiation treatment option to date. Advances in
radiation therapies have led to a decrease in the number of patients
treated by enucleation, or removal of an affected eye.

   Rivard commented, "Cesium-131's higher photon energies provide
improved dose homogeneity and allow the delivery of the required dose
while potentially reducing unnecessary dose to surrounding tissue."

   Rivard explained that intraocular melanoma tends be most common in
individuals over 40 years of age and is most commonly detected in
routine eye exams where the pupils are dilated. In other cases,
symptoms may include a dark spot on the iris or blurred vision. The
course of therapy is dictated by the size of the lesion, and whether
the cancer has spread throughout the eye or beyond.

   "Brachytherapy has been most effective for small- to medium-sized
tumors," added Rivard. "Under those conditions, we anticipate that in
most cases patients can be cured and their vision saved using
brachytherapy."

   IsoRay Medical received FDA (510k) clearance to market its
Cesium-131 seeds in March 2003. Cesium-131 is cleared for the
treatment of soft tissue cancers including prostate, eye, breast,
brain, liver, head and neck cancers, and other malignant diseases.

   For more information on Cesium-131 and Proxcelan, visit
www.proxcelan.com.

   About IsoRay, Inc.

   IsoRay, Inc., through its subsidiary, IsoRay Medical, Inc., is the
sole producer of the Proxcelan(TM) Cesium-131 brachytherapy seed, used
to treat prostate and other cancers. The Proxcelan(TM) seed offers a
significantly shorter half-life than the two other isotopes commonly
used for brachytherapy, which results in a substantially faster
delivery of therapeutic radiation, lower probability of cancer cell
survival and reduction of the longevity of common brachytherapy side
effects (a)(b). IsoRay is based in Richland, Washington. More
information is available about IsoRay at www.isoray.com.

   (a) Armpilia CI, Dale RG, Coles IP, et al. The Determination of
Radiobiologically Optimized Half-lives for Radionuclides Used in
Permanent Brachytherapy Implants. Int. J. Radiation Oncology Biol.
Phys. 2003; 55 (2): 378-385.

   (b) Prestidge B.R., Bice W.S., Jurkovic I., et al. Cesium-131
Permanent Prostate Brachytherapy: An Initial Report. Int. J. Radiation
Oncology Biol. Phys. 2005; 63 (1): 5336-5337.

   Safe Harbor Statement

   Statements in this news release about IsoRay's future
expectations, including: the advantages of our Proxcelan(TM)
Cesium-131 seed, future demand for IsoRay's Proxcelan(TM) Cesium-131
seed, whether the use of Cesium-131 to treat intraocular melanoma will
be successful in the initial and any future implants, and all other
statements in this release, other than historical facts, are
"forward-looking statements" within the meaning of the Private
Securities Litigation Reform Act of 1995 ("PSLRA"). This statement is
included for the express purpose of availing IsoRay, Inc. of the
protections of the safe harbor provisions of the PSLRA. It is
important to note that actual results and ultimate corporate actions
could differ materially from those in such forward-looking statements
based on such factors as successful completion of future research and
development activities, physician acceptance, training and use of
IsoRay's products, IsoRay's ability to successfully manufacture,
market and sell its products, IsoRay's ability to manufacture its
products in sufficient quantities to meet demand within required
delivery time periods while meeting its quality control standards,
IsoRay's ability to enforce its intellectual property rights, whether
additional studies support the conclusions of early clinical studies,
whether initial implants of Cesium-131 to treat intraocular melanoma
result in favorable patient outcomes, and other risks detailed from
time to time in IsoRay's reports filed with the SEC.

IsoRay, Inc.
Vice President
Lori Woods, lwoods@isoray.com
206-604-6400
or
Allen & Caron
Investors
Michael Mason, michaelm@allencaron.com
Media
Brian Kennedy, brian@allencaron.com
212-691-8087

Copyright Business Wire 2007
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.